Overview

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

Evaluate the progression-free survival (PFS) of benmelstobart combined with gemcitabine and cisplatin in first-line patients with advanced cholangiocarcinoma, and the progression-free survival (PFS) of benmelstobart combined with anlotinib in second-line patients with advanced cholangiocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

The Second Affiliated Hospital of Shandong First Medical University

Treatments:

Cisplatin
Gemcitabine